LRMR
Larimar Therapeutics Inc
Halal Rating :
Last Price
$3.35
Last updated:
Market Cap
-
7D Change
-3.74%
1 Year Change
-21.36%
Company Overview
Industries
Exchange
Next Earnings Date
Larimar Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. The company's lead compound, CTI-1601, is being developed for the treatment of Friedreich's ataxia, a rare genetic disease that causes nervous system damage and movement problems. The company is currently in the clinical development phase and does not yet generate revenue from product sales.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|
Company Impact
Help us evaluate Larimar Therapeutics Inc's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.